Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBT (2023 - 2025)

Historic EBT for Rallybio (RLYB) over the last 3 years, with Q3 2025 value amounting to $16.0 million.

  • Rallybio's EBT rose 24789.92% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 8006.85%. This contributed to the annual value of -$55.5 million for FY2024, which is 2342.29% up from last year.
  • Per Rallybio's latest filing, its EBT stood at $16.0 million for Q3 2025, which was up 24789.92% from -$9.4 million recorded in Q2 2025.
  • In the past 5 years, Rallybio's EBT registered a high of $16.0 million during Q3 2025, and its lowest value of -$19.6 million during Q4 2023.
  • Moreover, its 3-year median value for EBT was -$15.7 million (2024), whereas its average is -$11.8 million.
  • As far as peak fluctuations go, Rallybio's EBT crashed by 948.37% in 2024, and later surged by 24789.92% in 2025.
  • Quarter analysis of 3 years shows Rallybio's EBT stood at -$19.6 million in 2023, then skyrocketed by 45.93% to -$10.6 million in 2024, then surged by 250.9% to $16.0 million in 2025.
  • Its EBT stands at $16.0 million for Q3 2025, versus -$9.4 million for Q2 2025 and -$8.9 million for Q1 2025.